Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 24.89
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Thalys Medical Technology Group Inc. engages in the medical intensive business and operation services in China. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
